Skip to main content
. 2023 Aug 10;78(9):2343–2353. doi: 10.1093/jac/dkad242

Figure 4.

Figure 4.

Comparative efficacy of the human-simulated exposure of imipenem (500 mg q6h) alone and in combination with human-simulated exposure of funobactam (250 mg q6h) against four Klebsiella pneumoniae isolates. The comparative efficacy of human-simulated exposures of three commercially available β-lactam/β-lactamase inhibitors (imipenem/relebactam, ceftazidime/avibactam and meropenem/vaborbactam) against these isolates from previous unrelated experiments are also included. Data are means ± SDs. Imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam MICs for: KP 827 (>32, >64, 1 mg/L), KP 651 (1, ≤ 0.06, 1 mg/L), KP 741 (>32, 64, 1 mg/L) and KP 648 (4, 1, 2 mg/L). HSR, human-simulated regimen; IPM, imipenem; KP, Klebsiella pneumoniae.